<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000635</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 172</org_study_id>
    <secondary_id>11147</secondary_id>
    <nct_id>NCT00000635</nct_id>
  </id_info>
  <brief_title>Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine</brief_title>
  <official_title>Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in&#xD;
      treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus&#xD;
      ( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV&#xD;
      infection in patients with AIDS is often associated with skin sores and frequent recurrences.&#xD;
      Treatment with the drug acyclovir results in healing for most patients, but repeated&#xD;
      treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens,&#xD;
      other treatments need to be used. Trifluridine is an antiviral drug that is used for the&#xD;
      treatment of Herpes infections that occur in the eye. This study attempts to determine if&#xD;
      trifluridine is useful for treating HSV sores that have not healed after treatment with&#xD;
      acyclovir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HSV infection in patients with AIDS is often associated with skin sores and frequent&#xD;
      recurrences. Treatment with the drug acyclovir results in healing for most patients, but&#xD;
      repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this&#xD;
      happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for&#xD;
      the treatment of Herpes infections that occur in the eye. This study attempts to determine if&#xD;
      trifluridine is useful for treating HSV sores that have not healed after treatment with&#xD;
      acyclovir.&#xD;
&#xD;
      Patients receive at least 10 days (and up to 42 days) of treatment with topical trifluridine.&#xD;
      Trifluridine is applied in a thin fluid layer that overlaps the edges of the lesion.&#xD;
      Polymyxin B sulfate/bacitracin zinc ointment is then applied over the trifluridine. Lesions&#xD;
      are covered by a nonabsorbent dressing. Medication is applied every 8 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 1992</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>25</enrollment>
  <condition>Herpes Simplex</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacitracin zinc/Polymyxin B sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication: Included:&#xD;
&#xD;
          -  All medications deemed essential for best patient care, including zidovudine (AZT),&#xD;
             Pneumocystis carinii pneumonia (PCP) prophylaxis, and acute or maintenance therapies&#xD;
             for other opportunistic infections.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  HIV infection or diagnosis of AIDS.&#xD;
&#xD;
          -  Mucocutaneous Herpes simplex virus infection.&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Patients may be co-enrolled in other ACTG studies except for those in which treatments&#xD;
             are expected to generate neutropenia. Subjects aged 13 - 17 may be enrolled with&#xD;
             appropriate consent from parent or guardian.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acyclovir, ganciclovir, foscarnet, vidarabine or other investigational drugs with&#xD;
             potential anti-Herpes simplex virus activity.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Previous hypersensitivity reaction to trifluridine, polymyxin B or bacitracin.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunomodulators, lymphocyte replacement therapy or biologic response modifiers within&#xD;
             14 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kessler H A</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp. CORE Ctr.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kessler H, Weaver D, Benson C, Pottage J, Safrin S, Nevin T, Davis R, Owens S, Korvick J. ACTG 172: treatment of acyclovir-resistant (ACV-R) mucocutaneous herpes simplex virus (HSV) infection in patients with AIDS: open label pilot study of topical trifluridine (TFT). Int Conf AIDS. 1992 Jul 19-24;8(1):We55 (abstract no WeB 1056)</citation>
  </reference>
  <reference>
    <citation>Kessler HA, Hurwitz S, Farthing C, Benson CA, Feinberg J, Kuritzkes DR, Bailey TC, Safrin S, Steigbigel RT, Cheeseman SH, McKinley GF, Wettlaufer B, Owens S, Nevin T, Korvick JA. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):147-52. doi: 10.1097/00042560-199606010-00007.</citation>
    <PMID>8680885</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacitracin</keyword>
  <keyword>Polymyxin B</keyword>
  <keyword>Trifluridine</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Herpesviridae Infections</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Anti-Infective Agents, Local</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

